Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE
Tóm tắt
Từ khóa
Tài liệu tham khảo
American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care. 2010;33(Suppl. 1):S11–61.
Nathan DM, Buse JB, Davidson MB, American Diabetes Association, European Association for Study of Diabetes, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
Inzucchi SE, Bergenstal RM, Buse JB, American Diabetes Association, European Association for Study of Diabetes, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.
Blonde L. Current antihyperglycaemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med. 2010;123(Suppl. 3):S12–8.
IDF Clinical Guideline Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation; 2005. p. 26–8.
Holman RR, Thorne KI, Farmer AJ, 4-T Study Group, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716–30.
Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet. 2008;371:1073–84.
Hermansen K, Mortensen LS, Hermansen ML. Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease. Vasc Health Risk Manag. 2008;4:561–74.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Eng J Med. 2012;367:319–28.
Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin. 2009;25:691–700.
Liebl A, Jones S, Benroubi M, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries. Curr Med Res Opin. 2011;27:887–95.
Matthaei S, Bierwirth R, Fritsche A, et al. Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes. 2009;117:522–57.
Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B, PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial. Diab Obes Metab. 2009;11:45–52.
Holman RR, Farmer AJ, Davies MJ, 4-T Study Group, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–47.
Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia. 2009;52:1990–2000.
Heise T, Mathieu C, Hey-Hadavi J, Strack T, Lawrence D. Glycemic control with preprandial versus basal insulin in patients with type 2 diabetes mellitus poorly controlled by oral antidiabetes agents. Diabetes Technol Ther. 2010;12:135–41.
Bretzel RG, Eckhard M, Landgraf W, Owens D, Linn T. Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents basal or prandial insulin? The APOLLO trial and beyond. Diabetes Care. 2009;32(Suppl. 2):S260–5.
Arnolds S, Rave K. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes. Lancet. 2008;372:370–1.